Biotech Values

[wallstarb]

"In an impromptu discussion following the annual meeting, MNTA’s CMO, Jim Roach, expressed serious doubt that the FDA will approve Teva’s low-volume formulation based on the data reported in #msg-50939364."

MNTA haven't been able to figure out when/if their own products would get approval or when with any accuracy (it's always "very soon" with them) So I find it arrogant and foolish for them to comment on their competitions chances and timing for approval.